Becton, Dickinson and Company $BDX Shares Sold by Proffitt & Goodson Inc.

Proffitt & Goodson Inc. trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 292 shares of the medical instruments supplier’s stock after selling 93 shares during the quarter. Proffitt & Goodson Inc.’s holdings in Becton, Dickinson and Company were worth $50,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock valued at $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. increased its position in Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Becton, Dickinson and Company by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock valued at $707,872,000 after acquiring an additional 37,733 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 0.3%

Shares of BDX stock opened at $192.56 on Wednesday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a market cap of $55.19 billion, a PE ratio of 34.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.25. The business’s fifty day moving average is $189.41 and its 200-day moving average is $186.83. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Morgan Stanley lifted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $205.40.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last 90 days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.